Fondaparinux: 4 agencies, 2002–2023
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
The file has been open for more than a decade: 20.6 years separate the first record, 8 Nov 2002 at SMC (Scotland), from the most recent, 7 Jun 2023 at HAS (France).
AWMSG (Wales) changed its position: recommended on 22 May 2008, not recommended by 1 Nov 2011.
No assessment is on file from PBAC (Australia), PHARMAC (New Zealand), CIPM (Spain) and G-BA (Germany), each among the eight highest-volume agencies here.
Not every gap is a refusal: for fondaparinux, 3 submissions were never made — an outcome set by the company rather than the assessor.
7 distinct indication wordings are recorded for fondaparinux by the agencies that label one in English (AWMSG and SMC).
SMC (Scotland) was first to assess fondaparinux, on 8 Nov 2002; AWMSG (Wales) did not open a file until 22 May 2008 — a wide spread of 5.5 years between the earliest and latest system to look at it.
The record arrives in waves: 6 separate years each carry two or more decisions, spread across 11 years in total.
3 of the 4 agencies here assessed fondaparinux more than once, HAS (France) most often at 12 entries — repeat review is the norm for this molecule rather than the exception.
Coverage is narrow: only 4 of the 18 agencies here have assessed fondaparinux.
The full ledger for fondaparinux reads 10 other, 7 recommended, 3 non-submission and 1 not recommended.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| HAS (France) | 7 Jun 2023 | Re-assessment following post-listing study results | SMR moderate · ASMR V | source |
| HAS (France) | 2 Dec 2015 | Listing renewal (Transparency Committee) | SMR moderate | source |
| AWMSG (Wales) | 1 Nov 2011 | Treatment of adult patients with acute symptomatic spontaneous superficial vein thrombosis of the lower limbs without co… | not endorsed (non-submission) | source |
| SMC (Scotland) | 13 Dec 2010 | Treatment of acute symptomatic spontaneous superficial-vein thrombosis of the lower limbs without concomitant deep-vein thrombosis | not recommended | source |
| TLV (Sweden) | 18 May 2004 | LFN bifaller ansökan om Arixtra | general subsidy | source |
16 further decisions for fondaparinux, across 3 agencies, are not shown here. They link to 6 further source documents.
Related molecules
- rivaroxaban — same ATC class B01A — Antithrombotics
- apixaban — same ATC class B01A — Antithrombotics
- enoxaparin — same ATC class B01A — Antithrombotics
- dabigatran — same ATC class B01A — Antithrombotics
- ticagrelor — same ATC class B01A — Antithrombotics
- clopidogrel — same ATC class B01A — Antithrombotics
Coverage: 21 decisions for fondaparinux from 4 agencies, 2002 to 2023. Data to 7 Sep 2026. ATC class B01A — Antithrombotics. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.